Vyripharm
Vyripharm is a biopharmaceutical company developing diagnostics and therapeutics by integrating traditional and alternative medicine through its BioSync™ Platform.
Secondary Market Price
How Vyripharm Measures Up
To help you manage your Vyripharm equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
TBD
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Vyripharm's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Vyripharm Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Vyripharm's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Vyripharm Enterprises, Inc. is a biopharmaceutical and biotechnology company headquartered in Houston's Texas Medical Center. The company is focused on developing diagnostic and therapeutic applications that integrate traditional and alternative medicine. Its current activities include the development of the BioSync™ Platform, a data management system designed to integrate agribiopharmaceuticals with biopharmaceuticals and biotechnology. Vyripharm is also involved in research initiatives such as creating hemp and cannabis testing standards and developing theranostic approaches for viral infections like COVID-19. The company's specific founding date is not publicly disclosed, but it operates as an emerging innovator in its field.
Vyripharm has several recent developments underway. The company announced a sponsored research and facilities agreement with Colorado State University-Pueblo. It also signed a master drug program agreement with Regis Technologies, Inc. to manufacture antiviral agents for the diagnostic evaluation of COVID-19. In another partnership, Vyripharm and National Yang-Ming University signed a memorandum of understanding to develop a novel diagnostic approach for neurological disorders. The company's future plans include the continued advancement of its BioSync™ Platform and the development of new precision-based medical technologies, alongside ongoing global business development and strategic partnerships.
- The University of Texas MD Anderson Cancer Center
- Texas A&M University Health Science Center
- The Gulf Coast Consortia
- Co-Founder, Elias Jackson Jr.
- Co-Founder, Jerry Bryant
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Vyripharm worth joining?
Evaluating an offer from a private company like Vyripharm requires assessing the potential value of its equity compensation against your career goals. Tools like Prospect can help you analyze the potential upside of an equity package by using data-driven projections to compare opportunities.
What should I do with my Vyripharm stock?
Managing private stock involves complex tax and financial decisions, such as when to exercise options or sell shares. Platforms like Prospect provide customized, multi-year strategies to help you navigate these choices and maximize your potential returns.
Can you sell Vyripharm stock?
As Vyripharm is a private company, its stock is not publicly traded, but selling is sometimes possible during company-approved tender offers or on secondary markets. Prospect offers tender offer tools to help you decide how much to sell and which shares are the most tax-optimal to offload.
How can I find the value of my Vyripharm stock?
The value of private stock is typically determined by the 409A valuation or Fair Market Value (FMV), which is updated periodically. For a more dynamic forecast, Prospect uses proprietary predictive models to project your equity's future value based on market data and company performance signals.
What is Vyripharm's equity worth?
The total worth of Vyripharm's equity is not public information and fluctuates based on its performance, funding rounds, and market conditions. To understand what your specific stake might be worth, platforms like Prospect can help you model different financial scenarios and project your post-tax equity value.
What is Vyripharm's stock ticker symbol?
As a private company, Vyripharm does not have a stock ticker symbol because its shares are not available for trading on public stock exchanges. Ticker symbols are only assigned to companies after they complete an Initial Public Offering (IPO).
Can I buy or sell Vyripharm stock?
Selling stock in a private company like Vyripharm is sometimes possible through secondary markets or tender offers, while buying shares is typically restricted to accredited investors in specific funding rounds. Tools from Prospect are designed to help employees manage and decide when to sell the equity they already own, rather than facilitating purchases.
What is the criteria to buy or invest in Vyripharm stock?
Investing in a private company like Vyripharm is generally reserved for accredited investors and venture capital firms that participate in organized financing rounds. Prospect focuses on helping employees manage the equity they've been granted, rather than providing criteria for new investments.
